Investigational cell therapy for degenerative brain disorders takes center stage in a forum preview, offering insights into research direction and clinical interest.
Key Takeaways
- NKGen Biotech will present Troculeucel at the BIOCHINA Global Forum on 10 July 2026
- Company describes Troculeucel as a cryopreserved enhanced autologous natural killer cell therapy
- Troculeucel is currently being evaluated in a Phase 2 clinical trial for Alzheimer’s disease